Suchergebnisse - (Subject:"2494G1JF75")

PubPharm (97)

1

Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy : results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA)

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2009

von Negredo, E. | Miró, O. | Rodríguez-Santiago, B. | +35

2

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients

enthalten in: AIDS (London, England) | 2009

von De Meyer, S. | Lathouwers, E. | Dierynck, I. | +7

3

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients : 96-week analysis

enthalten in: AIDS (London, England) | 2009

von Mills, A. | Nelson, M. | Jayaweera, D. | +8

4

Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2009

von Brown, T. | McComsey, G. | King, M. | +3

5

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

enthalten in: AIDS (London, England) | 2009

von Smith, K. | Patel, P. | Fine, D. | +89

6

First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir

enthalten in: AIDS (London, England) | 2009

von van Vonderen, M. | Lips, P. | van Agtmael, M. | +7

7

Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients : a randomized trial

enthalten in: Archives of internal medicine | 2009

von Gross, R. | Tierney, C. | Andrade, A. | +73

CommentIn: Arch Intern Med. 2010 Jan 11;170(1):109-10. - PMID 20065210

8

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment

enthalten in: AIDS (London, England) | 2009

von Haubrich, R. | Riddler, S. | DiRienzo, A. | +96

CommentIn: AIDS. 2009 Aug 24;23(13):1727-9. - PMID 19571724

9

Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART : the ATAZIP study

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2009

von Mallolas, J. | Podzamczer, D. | Milinkovic, A. | +77

10

A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2009

von Gathe, J. | da Silva, B. | Cohen, D. | +8

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]